Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed glioblastoma patients are alive12 months following treatment.
Jeffrey Skolnik, MD on How INO-5401 Makes a Difference for Patients with GBM #ASCO2020 #ASCO @InovioPharma
By Editor